Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice
Moshe Elkabets, Ann M. Gifford, Christina Scheel, Bjorn Nilsson, Ferenc Reinhardt, Mark-Anthony Bray, Anne E. Carpenter, Karin Jirström, Kristina Magnusson, Benjamin L. Ebert, Fredrik Pontén, Robert A. Weinberg, Sandra S. McAllister
Moshe Elkabets, Ann M. Gifford, Christina Scheel, Bjorn Nilsson, Ferenc Reinhardt, Mark-Anthony Bray, Anne E. Carpenter, Karin Jirström, Kristina Magnusson, Benjamin L. Ebert, Fredrik Pontén, Robert A. Weinberg, Sandra S. McAllister
View: Text | PDF
Research Article

Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice

  • Text
  • PDF
Abstract

Systemic instigation is a process by which endocrine signals sent from certain tumors (instigators) stimulate BM cells (BMCs), which are mobilized into the circulation and subsequently foster the growth of otherwise indolent carcinoma cells (responders) residing at distant anatomical sites. The identity of the BMCs and their specific contribution or contributions to responder tumor growth have been elusive. Here, we have demonstrated that Sca1+cKit– hematopoietic BMCs of mouse hosts bearing instigating tumors promote the growth of responding tumors that form with a myofibroblast-rich, desmoplastic stroma. Such stroma is almost always observed in malignant human adenocarcinomas and is an indicator of poor prognosis. We then identified granulin (GRN) as the most upregulated gene in instigating Sca1+cKit– BMCs relative to counterpart control cells. The GRN+ BMCs that were recruited to the responding tumors induced resident tissue fibroblasts to express genes that promoted malignant tumor progression; indeed, treatment with recombinant GRN alone was sufficient to promote desmoplastic responding tumor growth. Further, analysis of tumor tissues from a cohort of breast cancer patients revealed that high GRN expression correlated with the most aggressive triple-negative, basal-like tumor subtype and reduced patient survival. Our data suggest that GRN and the unique hematopoietic BMCs that produce it might serve as novel therapeutic targets.

Authors

Moshe Elkabets, Ann M. Gifford, Christina Scheel, Bjorn Nilsson, Ferenc Reinhardt, Mark-Anthony Bray, Anne E. Carpenter, Karin Jirström, Kristina Magnusson, Benjamin L. Ebert, Fredrik Pontén, Robert A. Weinberg, Sandra S. McAllister

×

Figure 3

Sca1+cKit– hematopoietic BMCs are activated by instigating tumors.

Options: View larger image (or click on image) Download as PowerPoint
Sca1+cKit– hematopoietic BMCs are activated by instigating tumors.
   
(...
(A) FACS density plots representing the collection of the following BMC populations from instigating tumor-bearing mice: Sca1+cKit+ (population i), Sca1 depleted (population ii), and Sca1+cKit– (population iii). BMC population collected from control mice: Sca1+cKit– (population iv). (B) Relative average mass of resulting tumors 12 weeks after subcutaneous injection of responder-BMC mixtures. Tumor mass was normalized to the mass of control responder tumors that had grown on their own (3 separate experiments; n = 18 per group). (C) Histopathology of responding tumors resulting from the indicated admixtures. Top panel shows αSMA staining of myofibroblasts and pericytes (brown) and hematoxylin counterstaining of nuclei (blue). Bottom panel shows Masson’s trichrome staining for collagen (blue) and cell nuclei (dark pink). Scale bar: 100 μm. (D) Representation of Sca1+cKit– BMCs as percentage of total BMCs from mice bearing Matrigel plugs (gray), noninstigating tumors (blue), or instigating tumors (red). (E) Flow cytometric analysis of Sca1+cKit– BMCs from mice bearing Matrigel plugs (gray), noninstigating tumors (blue), or instigating tumors (red). Histograms represent staining intensity for indicating cell-surface antigen markers. Graph represents average percentage of Sca1+cKit– cells that were positive for the indicated cell-surface antigens (n = 4 per group). No significant differences were observed between groups. (F) Partial heat map showing differential gene expression analysis of Sca1+cKit– BMCs from instigator-bearing mice (BPLER, n = 4) compared with those from size-matched noninstigator-bearing mice (PC3, n = 5). (G) Fold change of GRN mRNA expression (qPCR) in sorted Sca1+cKit– BMCs prepared from indicated mice (n = 4 per group). Data are expressed as mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts